Israeli generic medicines producer Teva Pharmaceutical Industries (TEVA) announced Friday that it will discontinue the trial of fremanezumab for use in chronic cluster headache, which is part of the larger ENFORCE Phase III clinical development program.
from RTT - Biotech https://ift.tt/2sZBLaB
via IFTTT
No comments:
Post a Comment